このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

MediPharm Labs 将来の成長

Future 基準チェック /26

MediPharm Labsは、67.2%と22.7%でそれぞれ年率67.2%で利益と収益が成長すると予測される一方、EPSはgrowで64%年率。

主要情報

67.2%

収益成長率

64.0%

EPS成長率

Pharmaceuticals 収益成長	74.4%
収益成長率	22.7%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	17 May 2024

今後の成長に関する最新情報

Recent updates

MediPharm Labs (TSE:LABS) Is Using Debt Safely

May 29

Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

Mar 23

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Jan 10

MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

Sep 06

MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Apr 17

Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

Aug 20

Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates

May 23

Reflecting on MediPharm Labs' (TSE:LABS) Share Price Returns Over The Last Year

Jan 11

業績と収益の成長予測

TSX:LABS - アナリストの将来予測と過去の財務データ ( )CAD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	55	-3	N/A	N/A	2
12/31/2024	44	-9	N/A	N/A	2
3/31/2024	37	-14	-11	-11	N/A
12/31/2023	33	-13	-13	-12	N/A
9/30/2023	30	-16	-15	-14	N/A
6/30/2023	28	-19	-14	-14	N/A
3/31/2023	23	-26	-14	-14	N/A
12/31/2022	22	-30	-17	-16	N/A
9/30/2022	22	-46	-21	-20	N/A
6/30/2022	20	-46	-18	-17	N/A
3/31/2022	21	-48	-13	-13	N/A
12/31/2021	22	-55	-14	-13	N/A
9/30/2021	22	-64	-17	-16	N/A
6/30/2021	22	-72	-27	-26	N/A
3/31/2021	30	-63	-33	-28	N/A
12/31/2020	36	-66	-45	-38	N/A
9/30/2020	62	-39	-46	-29	N/A
6/30/2020	101	-20	-67	-40	N/A
3/31/2020	118	-15	-74	-45	N/A
12/31/2019	129	2	-58	-25	N/A
9/30/2019	107	1	-54	-27	N/A
6/30/2019	64	-4	-36	-12	N/A
3/31/2019	32	-8	-23	-4	N/A
12/31/2018	10	-8	-26	-11	N/A
9/30/2018	N/A	-6	-23	-10	N/A
6/30/2018	N/A	-4	-9	-4	N/A
3/31/2018	N/A	-2	-7	-3	N/A
12/31/2017	N/A	-1	N/A	0	N/A

アナリストによる今後の成長予測

収入対貯蓄率: LABS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: LABS今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: LABS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: LABSの収益 ( 22.7% ) Canadian市場 ( 7.3% ) よりも速いペースで成長すると予測されています。

高い収益成長: LABSの収益 ( 22.7% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: LABSの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

MediPharm Labs 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus estimates of losses per share improve by 25%

Consensus revenue estimates decrease by 11%

Consensus revenue estimates decrease by 25%, EPS upgraded

Consensus EPS estimates upgraded to CA$0.045 loss, revenue downgraded

Consensus revenue estimates increase by 47%, EPS downgraded

Consensus forecasts updated

Recent updates

MediPharm Labs Corp., Annual General Meeting, Jun 26, 2024

MediPharm Labs (TSE:LABS) Is Using Debt Safely

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

MediPharm Labs Corp. to Report Q1, 2024 Results on May 15, 2024

Consensus estimates of losses per share improve by 25%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

MediPharm Labs Corp. to Report Q4, 2023 Results on Mar 27, 2024

Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

New minor risk - Share price stability

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 11%

MediPharm Labs Corp. to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Share price stability

Tilray Brands, Inc. (NasdaqGS:TLRY) acquired 1000652011 Ontario Inc. from MediPharm Labs Corp. (TSX:LABS) for CAD 8.5 million.

MediPharm Labs Corp. Settles an Outstanding Claim for $9,000,000 with HEXO Corp

MediPharm Labs Corp. Launches New GMP Products to the Australian Medical Cannabis Market

MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

Medipharm Labs Corp. Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients

CEO & Director exercised options to buy CA$130k worth of stock.

Consensus revenue estimates decrease by 25%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MediPharm Labs Corp. to Report Q2, 2023 Results on Aug 14, 2023

MediPharm Labs Corp. Provides Update on US FDA Status

CEO & Director exercised options to buy CA$89k worth of stock.

CEO & Director exercised options to buy CA$93k worth of stock.

Consensus EPS estimates upgraded to CA$0.045 loss, revenue downgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MediPharm Labs Corp. to Report Q1, 2023 Results on May 15, 2023

High number of new and inexperienced directors

MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Consensus revenue estimates increase by 47%, EPS downgraded

MediPharm Labs Corp. (TSX:LABS) entered into a definitive arrangement agreement to acquire VIVO Cannabis Inc. (TSX:VIVO) from directors and officers of VIVO and others for CAD 11.1 million.

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

MediPharm Labs Corp. to Report Q3, 2022 Results on Nov 14, 2022

Onelife Botanicals Pty Ltd completed the acquisition of MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS).

Consensus revenue estimates fall by 20%

Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

MediPharm Labs Corp. to Report Q2, 2022 Results on Aug 15, 2022

Onelife Botanicals Pty Ltd entered into an agreement to acquire MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS) for AUD 6.9 million.

Dr. Paul Tam Resigns from the Board of Directors of MediPharm Labs Corp

Consensus revenue estimates fall by 27%

Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates

First quarter 2022 earnings: EPS and revenues miss analyst expectations

MediPharm Labs Corp. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to CA$0.25

High number of new and inexperienced directors

MediPharm Labs Corp., Annual General Meeting, Jun 30, 2022

MediPharm Labs Corp. Announces Management Changes

Consensus revenue estimates fall by 13%

Medipharm Labs Corp Launches CBG and Water-Soluble Products

Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022

MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022

Is MediPharm Labs (TSE:LABS) Using Too Much Debt?

Medipharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF

CEO of Asia Pacific & Director recently sold CA$87k worth of stock

MediPharm Labs Expands CBN Portfolio with Two New Products

Third quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.11 loss in 3Q 2020)

Second quarter 2021 earnings released: CA$0.05 loss per share (vs CA$0.02 loss in 2Q 2020)

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Consensus forecasts updated

Price target decreased to CA$0.65

MediPharm Labs Corp. Receives Canadian GMP Pharmaceutical Drug Establishment Licence

Founder & Chairman of the Board recently sold CA$483k worth of stock